REC-2282
- Generic Name
- REC-2282
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Recursion Pharmaceuticals Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT05130866
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Nicklaus Children's Hospital, Miami, Florida, United States
🇺🇸House Institute, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath